###begin article-title 0
###xml 74 79 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Sialoadhesin (CD169) Expression in CD14+ Cells Is Upregulated Early after HIV-1 Infection and Increases during Disease Progression
###end article-title 0
###begin p 1
Conceived and designed the experiments: BB Av MC. Performed the experiments: FG Rv FZ. Analyzed the data: FG Av FZ MC. Wrote the paper: Av.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 302 307 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
Sialoadhesin (CD169, siglec-1 or Sn) is an activation marker seen on macrophages in chronic inflammatory diseases and in tumours, and on subsets of tissue macrophages. CD169 is highly expressed by macrophages present in AIDS-related Kaposi's sarcoma lesions. It is also increased on blood monocytes of HIV-1 infected patients with a high viral load despite antiretroviral treatment.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 820 821 820 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 830 831 830 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 835 836 835 836 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 850 851 850 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 56 61 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 204 212 <span type="species:ncbi:9606">Patients</span>
###xml 234 239 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 288 293 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 434 437 <span type="species:ncbi:9606">men</span>
###xml 454 457 <span type="species:ncbi:9606">men</span>
###xml 519 524 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 591 599 <span type="species:ncbi:9606">patients</span>
###xml 625 630 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 845 850 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 852 860 <span type="species:ncbi:9606">patients</span>
We investigated expression of sialoadhesin in untreated HIV-1 and HHV-8 infected patients, by real-time PCR and FACS analysis to establish its expression in relation to infection and disease progression. Patients analysed were either HIV-1 seroconverters (n = 7), in the chronic phase of HIV-1 infection (n = 21), or in the AIDS stage (n = 58). Controls were HHV-8 infected, but otherwise healthy individuals (n = 20), and uninfected men having sex with men (n = 24). Sialoadhesin mRNA was significantly elevated after HIV-1, but not HHV-8 infection, and a further increase was seen in AIDS patients. Samples obtained around HIV-1 seroconversion indicated that sialoadhesin levels go up early in infection. FACS analysis of PBMCs showed that sialoadhesin protein was expressed at high levels by approximately 90% of CD14+ and CD14+CD16+cells of HIV-1+ patients with a concomitant 10-fold increase in sialoadhesin protein/cell compared with uninfected controls.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We have shown that sialoadhesin is induced to high levels on CD14+ cells early after HIV-1 infection in vivo. The phenotype of the cells is maintained during disease progression, suggesting that it could serve as a marker for infection and probably contributes to the severe dysregulation of the immune system seen in AIDS.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 666 667 666 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 675 676 675 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 713 716 713 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Decrion1">[1]</xref>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 19 25 <span type="species:ncbi:9606">humans</span>
###xml 278 281 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 506 511 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 infection of humans is traditionally divided into three stages: the acute phase lasting several weeks, when viral RNA levels are high and specific antibodies are low, followed by a relatively long period of chronic infection starting at the moment of seroconversion (when HIV-specific antibody tests become positive). Finally, the combined effects of the acute and chronic disease stage results in a total collapse of the immune system resulting in multiple opportunistic infections: the AIDS phase. HIV-1 infection is characterized by the expression of large amounts of proinflammatory cytokines, which are involved in immune suppression by promoting both CD4+ and CD8+ T cell apoptosis (for a review: see [1]). The cytokine signalling systems are further deregulated by virally encoded proteins such as Nef, Tat and Vpr. These chronic inflammatory conditions are linked to elevated virus production and immune dysfunction.
###end p 9
###begin p 10
###xml 224 227 224 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Cornelissen1">[2]</xref>
###xml 497 500 497 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Hartnell1">[3]</xref>
###xml 621 624 621 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Pulliam1">[4]</xref>
###xml 690 693 690 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Kirchberger1">[5]</xref>
###xml 843 846 839 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Hartnell1">[3]</xref>
###xml 848 851 844 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Crocker1">[6]</xref>
###xml 1920 1921 1916 1917 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1930 1931 1926 1927 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1935 1936 1931 1932 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 520 525 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 535 543 <span type="species:ncbi:9606">patients</span>
###xml 663 679 <span type="species:ncbi:169066">human rhinovirus</span>
###xml 919 924 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1055 1063 <span type="species:ncbi:9606">patients</span>
###xml 1113 1116 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1237 1242 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1252 1260 <span type="species:ncbi:9606">patients</span>
###xml 1277 1285 <span type="species:ncbi:9606">patients</span>
###xml 1287 1295 <span type="species:ncbi:9606">patients</span>
###xml 1381 1384 <span type="species:ncbi:9606">men</span>
###xml 1401 1404 <span type="species:ncbi:9606">men</span>
###xml 1486 1494 <span type="species:ncbi:9606">patients</span>
###xml 1553 1558 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1766 1771 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1781 1789 <span type="species:ncbi:9606">patients</span>
Applying Serial Analysis of Gene Expression (SAGE) to AIDS-related Kaposi's sarcoma (AIDS-KS) tissue and comparing its expression profile to that of normal skin, revealed several transcripts that were upregulated in AIDS-KS [2]. Of particular interest was the sialic acid binding receptor sialoadhesin (CD169, siglec-1 or Sn), which is seen on activated macrophages in chronic inflammation and in tumours, e.g. on macrophages found in multiple sclerosis, atherosclerosis, and rheumatoid arthritis [3], on monocytes from HIV-1 infected patients treated with antiretroviral therapy, especially those with a high viral load [4], and on dendritic cells infected with human rhinovirus strain 14 [5]. Sialoadhesin mediates cell-cell interactions by recognizing Neu5Acalpha2,3Gal in either N- or O-glycans on the surface of several leukocyte subsets [3], [6]. To evaluate expression of sialoadhesin during different stages of HIV-1 infection, we investigated sialoadhesin mRNA levels by real-time PCR in peripheral blood mononuclear cells (PBMCs) collected from patients participating in the Amsterdam Cohort Studies on HIV/AIDS. The expression level of sialoadhesin in AIDS-KS was compared with four control groups consisting of a-symptomatic HIV-1 infected patients, HHV-8 infected patients, patients with AIDS other than AIDS-KS, and non-infected controls belonging to the risk group (men having sex with men). Sialoadhesin mRNA levels were also compared in PBMCs from an additional set of patients sampled before and after the moment of seroconversion for HIV-1 (seroconverters). FACS analysis was used to investigate whether the upregulation of sialoadhesin represents an increased expression per cell, or an increase in cells expressing sialoadhesin. In asymptomatic HIV-1 infected patients, sialoadhesin protein expression was increased in the total PBMC fraction, including high levels on approximately 90% of both CD14+ and CD14+CD16+cells, with a mean two-fold expansion of the latter cell type.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
Expression of sialoadhesin mRNA
###end title 12
###begin p 13
###xml 88 95 88 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000257-g001">Fig. 1A</xref>
###xml 277 278 275 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 286 287 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 290 291 288 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 361 362 359 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 372 373 370 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 449 450 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 460 461 458 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 538 539 536 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 549 550 547 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 648 655 646 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000257-g001">Fig. 1A</xref>
###xml 881 882 879 880 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1281 1288 1277 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000257-g001">Fig. 1B</xref>
###xml 1668 1669 1664 1665 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 68 73 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
###xml 306 311 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
###xml 609 617 <span type="species:ncbi:9606">patients</span>
###xml 811 816 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 876 881 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 906 914 <span type="species:ncbi:9606">patients</span>
###xml 934 942 <span type="species:ncbi:9606">patients</span>
###xml 1051 1054 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1104 1109 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1220 1228 <span type="species:ncbi:9606">patients</span>
###xml 1271 1279 <span type="species:ncbi:9606">patients</span>
###xml 1368 1373 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1491 1496 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1601 1609 <span type="species:ncbi:9606">patients</span>
###xml 1690 1698 <span type="species:ncbi:9606">patients</span>
Sialoadhesin mRNA was quantified in PBMCs of patients infected with HIV-1 and/or HHV-8 (Fig. 1A). A highly significant difference (p</=0.0005) in sialoadhesin mRNA levels was seen in AIDS patients (both AIDS-KS and non-AIDS-KS, median copy numbers per group ranged from 4.83x103-2.35x104/104 PBMC), and in HIV-1 infected a-symptomatic patients (median = 2.49x103 copies/104 PBMC) when compared with non-infected risk-group patients (median = 2.69x102 copies/104 PBMC) or with patients with exclusively an HHV-8 infection (median = 4.28x102 copies/104 PBMC). Sialoadhesin levels between AIDS-KS and other AIDS patients did not differ significantly (Fig. 1A). These findings suggest that sialoadhesin mRNA is not specifically increased in AIDS-KS, as suggested by the earlier SAGE analysis, but is upregulated by HIV-1 infection. Differences in sialoadhesin copy number between HIV-1+ asymptomatics and AIDS patients, including AIDS-KS patients, were statistically significant, with higher expression in the AIDS group. This further upregulation during HIV pathogenesis could be related to a difference in HIV-1 copy numbers in PMBCs, as these were, not unexpected, found to differ significantly between AIDS and non-AIDS patients (p</=0.0001), with higher numbers in AIDS patients (Fig. 1B). However, sialoadhesin mRNA copy numbers were only moderately correlated with HIV-1 RNA copy numbers (Pearson correlation coefficient = 0.42, p = 0.0002). Overall, there was a trend that in PBMCs high HIV-1 intracellular copy numbers accompanied high sialoadhesin mRNA copy numbers, but this was not so for all patients. Sialoadhesin mRNA copy numbers did not correlate with CD4+ cell counts in AIDS patients (Pearson correlation coefficient = -0.125, p = 0.51).
###end p 13
###begin p 14
###xml 190 197 190 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000257-g001">Fig. 1C</xref>
###xml 445 446 445 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 456 457 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 473 474 473 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 484 485 484 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 25 30 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 121 126 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
###xml 168 173 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 245 250 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 510 515 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 678 683 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To analyse the effect of HIV-1 infection in more detail, sialoadhesin copy numbers were determined in samples from seven HIV-1 infected patients taken before and after HIV-1 seroconversion (Fig. 1C). The post-seroconversion sample was the first HIV-1 positive sample identified in individuals tested at three monthly intervals, therefore within three months of seroconversion. Indeed, sialoadhesin copy numbers increased from a median of 3.09x102 copies/104 PBMC to 3.00x103 copies/104 PBMC (p = 0.0016) after HIV-1 seroconversion, suggesting either an increase of sialoadhesin mRNA in a certain cell population, the expansion of a cell population expressing sialoadhesin after HIV-1 infection, or a loss of cells with low sialoadhesin expression, or a combination of these.
###end p 14
###begin title 15
Fluorescence-activated cell sorter (FACS) analysis of PBMCs
###end title 15
###begin p 16
###xml 307 308 307 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 337 338 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 342 343 342 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 495 502 495 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000257-t001">Table 1</xref>
###xml 563 569 563 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000257-g002">Fig. 2</xref>
###xml 584 585 584 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 606 607 606 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 611 612 611 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 655 656 655 656 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 662 664 662 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+ </sup>
###xml 672 673 672 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 740 741 740 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 898 905 898 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000257-t001">Table 1</xref>
###xml 945 946 945 946 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 955 956 955 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 960 961 960 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1082 1083 1082 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1087 1088 1087 1088 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1212 1219 1212 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000257-t001">Table 1</xref>
###xml 1285 1286 1285 1286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1340 1347 1340 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000257-t001">Table 1</xref>
###xml 416 421 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
###xml 839 844 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 854 862 <span type="species:ncbi:9606">patients</span>
###xml 1156 1161 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1171 1179 <span type="species:ncbi:9606">patients</span>
###xml 1323 1328 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1409 1414 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1424 1432 <span type="species:ncbi:9606">patients</span>
Increase of sialoadhesin expression at the mRNA level as measured by real-time PCR in our cohort could either mean that expression per cell has increased, that the number of sialoadhesin expressing cells has increased, or a combination of both. To differentiate between these possibilities, we analysed CD14+ cells and the subset of CD14+CD16+ cells from three healthy donors and three treatment-naive, asymptomatic HIV-1 infected patients for sialoadhesin protein expression by flow cytometry (Table 1). A representative example of the FACS analysis is shown in Fig. 2 (panel A: CD14+ cells, panel B: CD14+CD16+ cells). Staining with mAbs for either CD14+, CD16+ or CD169+ showed that sialoadhesin expression increases dramatically in CD14+ cell fractions, both in positive cell numbers as well as in the amount of molecules per cell, in HIV-1 infected patients compared with uninfected controls (Table 1). A median of approximately 90% of CD14+ and CD14+CD16+ cells expressed sialoadhesin at levels that were approximately 10-fold higher than in healthy donors. The number of CD14+CD16+ cells is increased approximately twofold in the PBMC population of HIV-1 infected patients compared with healthy controls (Table 1, median increase from 2,1% to 4,6%). The total percentage of CD14+ cells does not change notably after HIV-1 infection (Table 1, median percentage in healthy donors = 13,6% versus 10,4% in HIV-1 infected patients), nor does the amount of cells not expressing CD14, CD16 and sialoadhesin (66.47 and 67.28%, respectively), or the percentage of cells expressing sialoadhesin, but not CD14 and CD16 (0.21 and 0.42%, respectively).
###end p 16
###begin title 17
Discussion
###end title 17
###begin p 18
###xml 84 89 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 180 185 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 257 262 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 355 360 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 601 604 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 865 870 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Sialoadhesin mRNA and protein expression in PBMCs was significantly increased after HIV-1 infection in vivo. An additional raise was seen in AIDS-patients compared to asymptomatic HIV-1 infected patients. An analysis of blood samples taken before and after HIV-1 seroconversion indicated that the initial upregulation of sialoadhesin occurs rapidly after HIV-1 infection, and is maintained during the chronic phase of the infection. Sialoadhesin expression is increased after the moment of seroconversion (when specific antibody tests become positive), which is approximately 3 months after the acute HIV infection. Possibly, sialoadhesin levels already go up during the acute phase of the infection. However, due to the rarity of acute phase samples, it was not feasible in this study to assess if sialoadhesin expression is already increased in this stage of the HIV-1 infection.
###end p 18
###begin p 19
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 145 148 145 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Crocker2">[7]</xref>
###xml 200 203 200 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Crocker3">[8]</xref>
###xml 880 881 880 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 903 904 903 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 908 909 908 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1070 1071 1070 1071 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1173 1174 1173 1174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1178 1179 1178 1179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 3 7 <span type="species:ncbi:10090">mice</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 238 244 <span type="species:ncbi:9606">humans</span>
###xml 530 533 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
###xml 750 755 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 999 1002 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1126 1133 <span type="species:ncbi:9606">patient</span>
###xml 1206 1211 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1267 1275 <span type="species:ncbi:9606">patients</span>
In mice, approximately 106 molecules/cell of sialoadhesin are found, making it one of the most highly expressed surface molecules on macrophages [7]. Levels of mRNA and protein correlate well in mice [8]. Similar results were obtained in humans in this study, suggesting that sialoadhesin expression is mainly regulated at the transcriptional level, although it could be that cells with low sialoadhesin expression disappear, or that a novel cell subset expressing sialoadhesin emerges. Subsets of PBMC are generally different in HIV-infected patients compared with non-infected individuals, especially in the AIDS phase, when lymphocytes are significantly decreased and the monocyte fraction is increased. FACS analysis of blood cells obtained from HIV-1 infected individuals with a relatively high viral load showed that sialoadhesin is mainly expressed by and increased on CD14+ cells, including CD14+CD16+ monocytes. The potential influence of differences in the cellular subsets of healthy vs. HIV infected individuals seems limited here as the total amount of CD14+ monocytes does not differ appreciably between the two patient groups, although the percentage of CD14+CD16+ monocytes is larger after HIV-1 infection. However, to draw more firm conclusions more patients should be analysed.
###end p 19
###begin p 20
###xml 136 139 136 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Hartnell1">[3]</xref>
###xml 250 253 250 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Hartnell1">[3]</xref>
###xml 374 377 374 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Pulliam1">[4]</xref>
###xml 451 452 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 328 333 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 343 351 <span type="species:ncbi:9606">patients</span>
###xml 416 424 <span type="species:ncbi:9606">patients</span>
Sialoadhesin mRNA was found in a monocytic cell line, a promonocytic cell line, cells of the myeloerythroid lineage, but not in B-cells [3]. Expression of the protein was detected in tissue macrophages, but not in blood monocytes from healthy donors [3]. However, sialoadhesin was present on monocytes from treated, chronically HIV-1 infected patients with high viral loads [4], leading to the suggestion that these patients harbour a circulating CD14+ monocyte/macrophage hybrid phenotype with chronic inflammatory characteristics.
###end p 20
###begin p 21
###xml 129 133 129 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 137 138 137 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 148 151 148 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 155 156 155 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 230 233 230 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Passlick1">[9]</xref>
###xml 256 257 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 261 262 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Locher1">[10]</xref>
###xml 318 322 318 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Thieblemont1">[12]</xref>
###xml 379 381 379 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">++</sup>
###xml 413 417 413 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Nockher1">[11]</xref>
###xml 419 423 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Abel1">[13]</xref>
###xml 446 450 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Locher1">[10]</xref>
###xml 517 518 517 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 522 523 522 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Belge1">[14]</xref>
###xml 620 621 620 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 625 626 625 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 978 979 978 979 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 984 985 984 985 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1019 1023 1019 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Draude1">[15]</xref>
###xml 1238 1242 1238 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Abel1">[13]</xref>
###xml 1354 1358 1354 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Miller1">[16]</xref>
###xml 1365 1369 1365 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Meroni1">[17]</xref>
###xml 1376 1380 1376 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Nockher1">[11]</xref>
###xml 1388 1392 1388 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-vanderMeijden1">[18]</xref>
###xml 1400 1404 1400 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Lozano1">[19]</xref>
###xml 1424 1427 1424 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Pulliam1">[4]</xref>
###xml 1454 1455 1454 1455 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1628 1631 1628 1631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Pulliam1">[4]</xref>
###xml 297 302 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1066 1071 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1081 1089 <span type="species:ncbi:9606">patients</span>
###xml 1327 1332 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1487 1492 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Two monocyte subsets are currently recognized in peripheral blood, characterized by their level of CD14 and CD16 expression (CD14highCD16-, and CD14lowCD16+, representing approximately 90% and 10% of blood monocytes, respectively [9]). An expansion of CD14+CD16+ monocytes has been observed after HIV-1 infection [10]-[12] and other inflammatory conditions, while numbers of CD14++ monocytes do either not change [11], [13], or decrease slightly [10], in agreement with our observations. It has been assumed that CD14+CD16+ monocytes are a distinct "proinflammatory" subset of the monocyte lineage [14]. However, as CD14+CD16+ monocytes exhibit features of mature tissue macrophages (such as downregulation of CD11b, CD14, and CD33 expression, and upregulation of CD16 expression), it is also possible that they represent either an activated or a predifferentiated form of monocyte. In vitro experiments suggested the former, as inflammatory cytokines were able to induce a CD14+/CD16+- phenotype in cultured monocytes [15]. An increasing proportion of monocytes in HIV-1 infected patients show an activated, mature phenotype during disease progression when tested for markers such as CD11b, HLA-DR, CD45, CD16, TNF-alpha, PGE2, and IL-6 [13]. Furthermore, expression of several other molecules is increased on monocytes after HIV-1 infection, e.g. CD23 [16], CD36 [17], CD14 [11], CD126 [18], HLA-G [19], and sialoadhesin ([4] and this study). The CD169+ phenotype arises shortly after HIV-1 seroconversion, is maintained during progression to AIDS, and does not specifically occur during therapy failure, as suggested earlier [4].
###end p 21
###begin p 22
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Crocker4">[20]</xref>
###xml 202 206 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Munday1">[21]</xref>
###xml 232 235 232 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Pulliam1">[4]</xref>
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Crocker4">[20]</xref>
###xml 467 470 463 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Hartnell1">[3]</xref>
###xml 472 475 468 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Crocker1">[6]</xref>
###xml 771 775 767 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Weeks1">[22]</xref>
###xml 1049 1052 1045 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Kirchberger1">[5]</xref>
###xml 1175 1179 1171 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Avril1">[23]</xref>
###xml 1774 1778 1770 1774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Aggarwal1">[24]</xref>
###xml 1846 1850 1842 1846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Gabrilovich1">[25]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 215 220 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 631 634 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 736 739 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 749 757 <span type="species:ncbi:9606">patients</span>
###xml 929 948 <span type="species:ncbi:12131">human rhinovirus 14</span>
###xml 1412 1415 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Human sialoadhesin is highly upregulated in certain (inflammatory) diseases such as multiple sclerosis, atherosclerosis, and rheumatoid arthritis, in breast cancer tumour-infiltrating macrophages [20], [21], and by HIV-1 infection ([4], and this study). The function of sialoadhesin is still not completely clear [20]. Sialoadhesin mediates cell-cell interactions by recognizing Neu5Acalpha2,3Gal in either N- or O-glycans on the surface of several leukocyte subsets [3], [6], suggesting that sialoadhesin could be involved in adhesion processes. Monocytes (and also lymphocytes) show increased adhesion to endothelial cells after HIV infection, leading to an increase in cardiovascular disease, atherosclerosis and Kaposi's sarcoma in HIV-positive patients (reviewed in [22]). Increased expression of sialoadhesin could be related to this phenomenon. On the other hand, dendritic cells express sialoadhesin after infection with human rhinovirus 14, and here it was shown to function as an inhibitory receptor involved in inducing anergy in T-cells [5]. CD33-related members of the siglec family (subgroup 2) have been shown to have inhibitory functions in the immune system [23]. It is likely that the distinct subgroup 1 siglecs (siglec-1, -2, and -4) have similar, negative regulatory functions in the immune system. Elevated, enduring expression of sialoadhesin in chronic inflammatory conditions (including HIV infection) and certain types of cancer, probably induced by high-level cytokine expression, then has a lasting negative, inhibitory effect on the immune system that finally results in opportunistic infections and/or the occurrence of tumours due to immune system malfunction. Chronic inflammation is a risk factor for many types of cancer (for a review, see [24]), and is characterized by immune system unresponsiveness (see e.g. [25]).
###end p 22
###begin p 23
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Crocker5">[26]</xref>
###xml 359 363 359 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Vanderheijden1">[27]</xref>
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Delputte1">[28]</xref>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Geyer1">[29]</xref>
###xml 542 546 542 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Feizi1">[30]</xref>
###xml 218 222 <span type="species:ncbi:9823">pigs</span>
###xml 323 328 <span type="species:ncbi:28344?0.9455645161290323">PRRSV</span>
###xml 469 474 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Only higher animals and a few microorganisms can synthesize sialic acids, but some pathogens have found ways to capture these sugars from their hosts (reviewed in [26]), possibly to provide an immunologic disguise. In pigs, siglec-1 can act as an endocytic receptor for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), a single-stranded RNA virus [27], whereby sialic acids on the virus particle are essential for infection of porcine macrophages [28]. The HIV-1 envelope protein gp120 is highly glycosylated and sialylated [29], [30], suggesting that the presence of sialic acids on the virion surface influences host production of sialoadhesin.
###end p 23
###begin p 24
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Concluding, we have shown that early after HIV-1 infection, sialoadhesin is induced to high levels on CD14+ cells of the blood. The phenotype of the cells is maintained during disease progression, suggesting that it could serve as a marker for infection and probably contributes to the severe dysregulation of the immune system seen in AIDS.
###end p 24
###begin title 25
Materials and Methods
###end title 25
###begin title 26
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics
###end title 26
###begin p 27
###xml 546 550 546 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Polstra1">[31]</xref>
###xml 717 721 717 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Renwick1">[32]</xref>
###xml 850 853 850 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Cornelissen1">[2]</xref>
###xml 34 46 <span type="species:ncbi:9606">participants</span>
###xml 82 85 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 261 269 <span type="species:ncbi:9606">patients</span>
###xml 279 287 <span type="species:ncbi:9606">patients</span>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
###xml 320 325 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 361 366 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 441 444 <span type="species:ncbi:9606">men</span>
###xml 461 464 <span type="species:ncbi:9606">men</span>
###xml 482 490 <span type="species:ncbi:9606">patients</span>
###xml 571 579 <span type="species:ncbi:9606">patients</span>
###xml 731 739 <span type="species:ncbi:9606">patients</span>
###xml 786 794 <span type="species:ncbi:9606">patients</span>
###xml 919 926 <span type="species:ncbi:9606">patient</span>
Blood samples were collected from participants of the Amsterdam Cohort Studies on HIV/AIDS (). PBMCs isolated from a total of 131 individuals, all Caucasian homosexual males, were selected for this study. They were divided into the following groups: 24 AIDS-KS patients, 34 AIDS patients, 20 HHV-8 infected patients, 21 HIV-1 infected a-symptomatic patients, 7 HIV-1 seroconverters, and 24 non-infected controls belonging to the risk group (men having sex with men). Of the AIDS-KS patients, 13 ( = 54%) had quantifiable HHV-8 DNA in their PBMCs [31]. Of the non-KS AIDS patients, 5 ( = 15%) had quantifiable HHV-8 DNA in their PBMCs, and 15 (44%) were seropositive for HHV-8 in either an ORF65 and/or an ORF73 ELISA [32]. AIDS-KS patients have been analysed separately from other AIDS patients, as high expression of sialoadhesin in AIDS-KS lesions [2] suggested that levels of sialoadhesin could be different in this patient group.
###end p 27
###begin title 28
RNA and DNA extraction
###end title 28
###begin p 29
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 86 90 86 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Boom1">[33]</xref>
Nucleic acids were isolated from 2.5x105 PBMCs using silica and guanidium thiocyanate [33] in a final elution volume of 62.5 microl. RNA and DNA can be isolated simultaneously by this method.
###end p 29
###begin title 30
Real-time quantitative PCR assay
###end title 30
###begin p 31
###xml 509 510 497 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 673 674 633 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1083 1084 1007 1008 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1515 1519 1427 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000257-Polstra1">[31]</xref>
###xml 2531 2532 2399 2400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1208 1213 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Copy numbers of sialoadhesin were determined with TaqMan assays using primers (upstream primer: 5'CACCTCCAAGTGAAGTATGCCC 3', downstream primer: 5' CCTGGAAGG ATGTTCCTCCC 3', probe: 5'AAGGGTGTGAAGATCCTCCTCAGCCC 3') designed with Primer Express software (ABI, Foster City, CA, USA). First, 2.5 microl isolated RNA was converted into cDNA following the instructions in the ABI Taqman Reverse Transcription reagents kit (ABI, Foster City, CA, USA). Each RT reaction contained 1 microl 10xRT buffer, 2.2 microl MgCl2 (25 mM), 2 microl dNTPs (10 mM) 1.5 microl random hexamers (50 microM), 0.2 RNase inhibitor (20 U/microl), 0.35 microl multiscribe RT (50 U/microl), 0.35 microl H2O and 2.5 microl sample eluate ( = 10,000 cell equivalents). The RT-reaction started with 10 min. 25degreesC, 30 min. 48degreesC and 5 min. 95degreesC. Subsequent PCR reactions were done according to Platinum(R) Quantitative PCR Supermix UDG (Invitrogen Life Technologies, Carlsbad, USA). Each reaction contained 10 microl RT-reaction and 40 microl of PCR mixture consisting of 25 microl supermix, 3.6 mM MgCl2, 0.9 microM forward primer and reverse primer, 0.2 microM Taqman probe and 1 microl ROX reference dye (50x concentration). HIV-1 copy numbers in PBMCs were measured with a gag-specific Taqman assay (upstream primer: 5' AAAGAGACCATCAATGAGGAAGCT 3', downstream primer: 5' TCTGGCCTGGTGCAATAGG 3', probe: 5' TGCACTGGATGCACTCTATCC CATTCTG 3'). HHV-8 DNA copy numbers in PBMCs were measured with an ORF65 Taqman assay described earlier [31]. As a control, a DNA assay was performed for beta-actin using 5 microl eluate ( = 20,000 cell equivalents) as input. The beta-actin reaction conditions were the same except for the primer and probe concentrations (0.3 microM forward and reverse primers and 0.2 microM Taqman probe). Following the activation of UDG (2 min, 50degreesC) and activation of Platinum(R) Taq DNA polymerase (10 min 95degreesC), 45 cycles (15 sec 95degreesC, and 1 min 60degreesC) were performed on an ABI 7700 Sequence Detection System (ABI, Foster City, CA, USA). The threshold cycle (Ct) for each sample of the standard curve was plotted against the input copy number. The value of Ct was determined by the first cycle number at which fluorescence was greater than the set threshold value. For accurate comparison of the samples the threshold was the same for all the experiments. Linear regression was used to determine the copy number of the experimental samples. The sialoadhesin copy numbers measured were converted to copies/104 PBMC. All samples were tested in duplicate. As a control for cross contamination samples consisting of distilled water were also subjected to the isolation method and the extracts were tested with all assays. The Ct for all these "no-template" samples was always >45 cycles.
###end p 31
###begin title 32
Fluorescence-activated cell sorter (FACS) analysis
###end title 32
###begin p 33
###xml 154 159 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 183 188 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
PBMCs were isolated by density centrifugation on Lymphoprep (Axis-Shield PoC AS, Norway) from three healthy donors and three treatment-naive asymptomatic HIV-1 infected patients with HIV-1 plasma loads between 90,000 and 100,000 copies vRNA/ml.
###end p 33
###begin p 34
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 527 528 518 519 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 221 226 <span type="species:ncbi:10090">Mouse</span>
###xml 232 237 <span type="species:ncbi:9606">human</span>
###xml 515 519 <span type="species:ncbi:9925">goat</span>
###xml 534 539 <span type="species:ncbi:10090">mouse</span>
###xml 591 596 <span type="species:ncbi:10090">mouse</span>
###xml 614 618 <span type="species:ncbi:9925">goat</span>
###xml 624 629 <span type="species:ncbi:10090">mouse</span>
Subsequently, 0.5-1x106 cells were used for staining. All samples for FACS analysis were prepared within 2 hrs after blood was drawn. Whole PBMC fraction was gated and analysed for the expression of CD14, CD16 and CD169. Mouse anti-human monoclonal antibodies (MAbs) against the following molecules were used: PE-conjugated CD14 (Becton Dickinson, USA), FITC-conjugated CD16 (Peliclustertrade mark monoclonal antibodies, Sanquin, The Netherlands), and CD169 (Serotec, UK), which was detected with an APC-conjugated goat (F(ab')2 anti-mouse IgG (Caltag Laboratories). The staining order was: mouse anti-CD169, then goat anti-mouse, and finally the directly labelled antibodies, with washing steps in between to minimize cross-reactivity. The samples were subsequently analysed on a FACS Caliber flow cytometer (Becton Dickinson, USA). Unstained cells and appropriate isotype-matched controls were used to determine positive CD14, CD16 and CD169 staining.
###end p 34
###begin title 35
Statistical analysis
###end title 35
###begin p 36
Overall comparison was done using analysis of variance (ANOVA). If statistical significance was obtained for a variable, a post-hoc analysis was done with application of the Student's t test for group-by-group comparisons. All statistical analyses were performed with SAS software (SAS version 8.02, SAS Institute, Cary, NC, USA).
###end p 36
###begin p 37
###xml 13 25 <span type="species:ncbi:9606">participants</span>
###xml 61 64 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We thank the participants in the Amsterdam Cohort Studies on HIV/AIDS, Dr Gerrit Jan Weverling (Crucell NV, Leiden, The Netherlands) for help with the statistical analysis, and Margreet Bakker (Dept. of Medical Microbiology, AMC, The Netherlands) for help with selection of samples.
###end p 37
###begin title 38
References
###end title 38
###begin article-title 39
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV and inflammation.
###end article-title 39
###begin article-title 40
Gene expression profile of AIDS-related Kaposi's sarcoma.
###end article-title 40
###begin article-title 41
###xml 20 25 <span type="species:ncbi:9606">human</span>
Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations.
###end article-title 41
###begin article-title 42
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Invasive chronic inflammatory monocyte phenotype in subjects with high HIV-1 viral load.
###end article-title 42
###begin article-title 43
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human rhinoviruses inhibit the accessory function of dendritic cells by inducing sialoadhesin and B7-H1 expression.
###end article-title 43
###begin article-title 44
###xml 79 85 <span type="species:ncbi:10090">murine</span>
Purification and properties of sialoadhesin, a sialic acid-binding receptor of murine tissue macrophages.
###end article-title 44
###begin article-title 45
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 32 37 <span type="species:ncbi:9940">sheep</span>
Mouse macrophage hemagglutinin (sheep erythrocyte receptor) with specificity for sialylated glycoconjugates characterized by a monoclonal antibody.
###end article-title 45
###begin article-title 46
Sialoadhesin, a macrophage sialic acid binding receptor for haemopoietic cells with 17 immunoglobulin-like domains.
###end article-title 46
###begin article-title 47
###xml 73 78 <span type="species:ncbi:9606">human</span>
Identification and characterization of a novel monocyte subpopulation in human peripheral blood.
###end article-title 47
###begin article-title 48
###xml 111 114 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Expression patterns of Fc gamma receptors, HLA-DR and selected adhesion molecules on monocytes from normal and HIV-infected individuals.
###end article-title 48
###begin article-title 49
###xml 97 100 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients.
###end article-title 49
###begin article-title 50
###xml 75 103 <span type="species:ncbi:12721">human immunodeficiency virus</span>
CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection.
###end article-title 50
###begin article-title 51
###xml 58 86 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Heterogeneity of peripheral blood monocyte populations in human immunodeficiency virus-1 seropositive patients.
###end article-title 51
###begin article-title 52
The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF.
###end article-title 52
###begin article-title 53
###xml 59 64 <span type="species:ncbi:9606">human</span>
Distinct scavenger receptor expression and function in the human CD14(+)/CD16(+) monocyte subset.
###end article-title 53
###begin article-title 54
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Increased expression of CD23 (Fc(epsilon) receptor II) by peripheral blood monocytes of aids patients.
###end article-title 54
###begin article-title 55
###xml 58 61 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Increased CD36 expression on circulating monocytes during HIV infection.
###end article-title 55
###begin article-title 56
###xml 87 90 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
IL-6 receptor (CD126'IL-6R') expression is increased on monocytes and B lymphocytes in HIV infection.
###end article-title 56
###begin article-title 57
###xml 31 36 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule.
###end article-title 57
###begin article-title 58
The potential role of sialoadhesin as a macrophage recognition molecule in health and disease.
###end article-title 58
###begin article-title 59
Sialic acid binding receptors (siglecs) expressed by macrophages.
###end article-title 59
###begin article-title 60
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The role of HIV-1 activated leukocyte adhesion mechanisms and matrix metalloproteinase secretion in AIDS pathogenesis (Review).
###end article-title 60
###begin article-title 61
Negative regulation of leucocyte functions by CD33-related siglecs.
###end article-title 61
###begin article-title 62
Inflammation and cancer: how hot is the link?
###end article-title 62
###begin article-title 63
Mechanisms and functional significance of tumour-induced dendritic-cell defects.
###end article-title 63
###begin article-title 64
Siglecs, sialic acids and innate immunity.
###end article-title 64
###begin article-title 65
###xml 40 91 <span type="species:ncbi:28344">porcine reproductive and respiratory syndrome virus</span>
Involvement of sialoadhesin in entry of porcine reproductive and respiratory syndrome virus into porcine alveolar macrophages.
###end article-title 65
###begin article-title 66
Porcine arterivirus infection of alveolar macrophages is mediated by sialic acid on the virus.
###end article-title 66
###begin article-title 67
###xml 17 45 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120.
###end article-title 67
###begin article-title 68
AIDS and glycosylation.
###end article-title 68
###begin article-title 69
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 64 72 <span type="species:ncbi:9606">Patients</span>
Human Herpesvirus 8 Load in Matched Serum and Plasma Samples of Patients with AIDS-Associated Kaposi's Sarcoma.
###end article-title 69
###begin article-title 70
###xml 19 38 <span type="species:ncbi:37296">human herpesvirus 8</span>
###xml 46 49 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma.
###end article-title 70
###begin article-title 71
Rapid and simple method for purification of nucleic acids.
###end article-title 71
###begin title 72
Figures and Tables
###end title 72
###begin title 73
###xml 63 68 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Real-time PCR analysis of sialoadhesin mRNA levels in PBMCs of HIV-1 infected patients and controls.
###end title 73
###begin p 74
###xml 928 929 924 925 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 114 119 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 162 170 <span type="species:ncbi:9606">Patients</span>
###xml 202 210 <span type="species:ncbi:9606">patients</span>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
###xml 356 361 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 371 379 <span type="species:ncbi:9606">patients</span>
###xml 457 462 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 472 480 <span type="species:ncbi:9606">patients</span>
###xml 490 498 <span type="species:ncbi:9606">patients</span>
###xml 602 609 <span type="species:ncbi:9606">patient</span>
###xml 635 640 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 680 688 <span type="species:ncbi:9606">patients</span>
###xml 730 735 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 777 782 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 805 813 <span type="species:ncbi:9606">patients</span>
###xml 817 825 <span type="species:ncbi:9606">patients</span>
###xml 870 875 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 889 897 <span type="species:ncbi:9606">patients</span>
###xml 923 928 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 930 938 <span type="species:ncbi:9606">patients</span>
###xml 1058 1066 <span type="species:ncbi:9606">patients</span>
###xml 1084 1089 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1150 1155 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1184 1191 <span type="species:ncbi:9606">patient</span>
###xml 1292 1295 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A. Real-time PCR analysis of sialoadhesin mRNA levels in PBMCs derived from five sets of patients with or without HIV-1 infection at different stages of disease. Patients with AIDS but not AIDS-KS, and patients with AIDS-KS were analysed separately. Levels were significantly different (p</=0.0005) between uninfected controls/HHV-8 infected patients, and HIV-1 infected patients, respectively. Levels were also significantly different (p</=0.0005) between HIV-1 infected patients and AIDS patients. Significant differences are indicated with an asterisk. No significant differences were found between patient groups not infected with HIV-1 (p = 0.1), or between AIDS and AIDS-KS patients (p = 0.14). B. Real-time PCR analysis of HIV-1 mRNA levels in PBMCs derived from either HIV-1 infected asymptomatic patients or patients with AIDS (including AIDS-KS). The elevated HIV-1 load in AIDS patients compared to asymptomatic HIV-1+ patients is highly significant (p</=0.0001). C. Real-time PCR analysis of sialoadhesin mRNA levels in PBMCs obtained from eight patients before and after HIV-1 seroconversion. Sialoadhesin mRNA was analysed in the first HIV-1 seropositive sample of each patient, which is within three months from the real seroconversion event in the Amsterdam Cohort Studies on HIV/AIDS, as samples are taken on a three-monthly basis.
###end p 74
###begin title 75
###xml 64 69 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 94 101 <span type="species:ncbi:9606">patient</span>
Expression of CD14, CD16, and sialoadhesin on monocytes from an HIV-1 infected and uninfected patient.
###end title 75
###begin p 76
###xml 42 43 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 178 179 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 300 301 300 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 305 306 305 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 442 443 442 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 447 448 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 93 98 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 108 115 <span type="species:ncbi:9606">patient</span>
###xml 261 266 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 276 283 <span type="species:ncbi:9606">patient</span>
###xml 530 535 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 545 552 <span type="species:ncbi:9606">patient</span>
A. Sialoadhesin (CD169) expression on CD14+ cells from a healthy human control (left) and an HIV-1 infected patient (right). The mean fluorescent intensity of CD169 from the CD14+ cells increases from 26 in the control cells (left) to 286 in the cells from the HIV-1 infected patient (right). B. CD14+CD16+ cells were gated and their expression of sialoadhesin is shown in the histograms. The mean fluorescent intensity of CD169 from the CD14+CD16+ cells increases from 17 in the control cells (left) to 158 in the cells from the HIV-1 infected patient (right). The data are representative of three experiments.
###end p 76
###begin title 77
Percentage of cells expressing CD14, CD16, and/or sialoadhesin of the total PBMC fraction, as determined by FACS analysis
###end title 77
###begin p 78
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 78
###begin p 79
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: There was no specific funding for this study.
###end p 79

